临床PI
虞先濬 教授
教授,博士生导师
E-mail: yuxianjun88@hotmail.com
 

复旦大学胰腺肿瘤研究所所长/复旦大学附属肿瘤医院胰腺外科主任,中国抗癌协会胰腺癌专业委员会侯任主任委员,中国抗癌协会胰腺癌专业委员会多学科协作学组组长(CSPAC),中国抗癌协会胰腺癌专业委员会神经内分泌肿瘤学组副组长(CSNET),国家自然科学基金委杰出青年基金获得者,Cancer Letters中国上海编辑部执行主任,Cancer Letters编委,《CCR》《Current Molecular Medicine》,《Journal of Liver》等国际著名杂志编委/特约审稿专家。  

长期致力于胰腺癌基临床-础转化型研究,针对如何提升胰腺癌外科综合治疗水平,进而提高患者的长期生存这一问题,开展了系统的、逐步递进的应用基础和转化医学研究。目前主刀胰腺癌根治术500余例/年,实施胰腺癌多学科综合治疗近3000/年。获得国家自然科学基金委杰出青年基金,国家自然科学基金中德科学中心重点国际合作项目,国家自然科学基金面上项目3项、省部级项目7项;入选上海市卫生系统新百人计划上海市科技启明星-启明星跟踪计划,获明治生命科学奖杰出奖、上海市优秀发明奖金奖;带领团队获得国家自然科学基金18项,省部级项目30项;总计经费达2500万。近5年以通讯/第一作者在JCOAnnals of SurgeryCell ResearchClinical Cancer ResearchOncogeneBritish Journal of SurgerySurgeryAnnals of Surgical Oncology等国际著名外科与肿瘤学杂志上发表SCI论文65篇,总影响因子300分。作为第一发明人获8项国家授权专利。


主要学术兼职:

中国抗癌协会胰腺癌专业委员会

侯任主任委员

中国抗癌协会

理事

中国抗癌协会胆道肿瘤专业委员会

委员

上海市抗癌协会胰腺癌专业委员会

常委兼秘书长

上海市抗癌协会

理事

Cancer Letters

编委,Shanghai Office执行主编

Journal of Cytology & Histology

编委

Oncologic Reports

编委

Translational Medicine

编委

中国癌症杂志

编委


获奖情况:  

2014   上海市科技发明奖金奖“胰空肠吻合器械的优化”

2013   上海市新百人计划

2012   上海市医务系统科技创新标兵

2011   明治生命科学奖杰出奖”“胰腺癌综合治疗

2009   上海市医学奖三等奖可切除胰腺癌分阶段综合治疗

2003   中华医学会优秀论文奖三等奖

 

论著(参与部分章节编写,约2万字)

《临床外科学》、《现代外科学》、《实用外科学》、《普外科诊疗常规》


研究领域:

  1.优化改善胰腺癌吻合技术进一步降低胰腺癌术后胰漏;
  2.开展外科微创腹腔镜技术引导下术中放疗的新方法,突破了传统放疗在胰腺癌上运用的局限性;
  3.探索胰腺癌淋巴转移特点,指导胰腺癌淋巴清扫并行针对性淋巴导向治疗;
  4.探索胰腺癌生物学特性,进一步转化应用于临床治疗。

研究团队:



代表性论著:

  1. Shunrong Ji#, Bo Zhang#, Jiang Liu, Yi Qin, Chen Liang, Si Shi, Kaizhou Jin, Dingkong Liang, Wenyan Xu, Huaxiang Xu, Wenquan Wang, Chuntao Wu, Liang Liu, Chen Liu, Jin Xu, Quanxing Ni, Xianjun Yu*. ALDOA functions as an oncogene in the highly metastatic pancreatic cancer. Cancer Lett, 2016 Apr 28; 374(1):127-35.
  2. Shunrong Ji#,Yi Qin#, Chen Liang#, Run Huang, Si Shi, Jiang Liu, Kaizhou Jin, Dingkong Liang, Wenyan Xu, Bo Zhang, Liang Liu, Chen Liu, Jin Xu, Quanxing Ni, Paul J. Chiao, Min Li, Xianjun Yu*. FBW7 (F-box andWDRepeat Domain-Containing 7) Negatively Regulates Glucose Metabolism by Targeting the c-Myc/TXNIP (Thioredoxin-Binding Protein) Axis in Pancreatic Cancer. Clin Cancer Res, 2016 Aug 1; 22(15):3950-60.
  3. Chen Liang#, Yi Qin#, Bo Zhang, Shunrong Ji, Si Shi, Wenyan Xu, Jiang Liu, Jinfeng Xiang, Dingkong Liang, Qiangsheng Hu, Liang Liu, Chen Liu, Guopei Luo, Quanxing Ni, Jin Xu*, Xianjun Yu*. Energy sources identify metabolic phenotypes in pancreatic cancer. Acta Biochim Biophys Sin (Shanghai), 2016 Nov; 48(11):969-979.
  4. Chen Liang#, Yi Qin#, Bo Zhang, Shunrong Ji, Si Shi, Wenyan Xu, Jiang Liu, Jinfeng Xiang, Dingkong Liang, Qiangsheng Hu, Quanxing Ni, Jin Xu*, Xianjun Yu*. Metabolic plasticity in heterogeneous pancreatic ductal adenocarcinoma. Biochim Biophys Acta, 2016 Sep 4; 1866(2):177-188.
  5. Zhang B#, Xu J#, Li C, Shi S, Ji S, Xu W, Liu J, Jin K, Liang D, Liang C, Liu L, Liu C, Qin Y, Yu X*. MBD1 is an Epigenetic Regulator of KEAP1 in Pancreatic Cancer. Curr Mol Med, 2016; 16(4):404-11.
  6. Shi S#, Xu J#, Zhang B, Ji S, Xu W, Liu J, Jin K, Liang D, Liang C, Liu L, Liu C, Qin Y, Yu X*. VEGF Promotes Glycolysis in Pancreatic Cancer via HIF1α Up-Regulation. Curr Mol Med, 2016; 16(4):394-403.
  7. Liu J#, Ji S#, Liang C, Qin Y, Jin K, Liang D, Xu W, Shi S, Zhang B, Liu L, Liu C, Xu J, Ni Q, Yu X*. Critical role of oncogenic KRAS in pancreatic cancer (Review). Mol Med Rep, 2016 Jun; 13(6):4943-9.
  8. Liang D#, Shi S#, Xu J#, Zhang B, Qin Y, Ji S, Xu W, Liu J, Liu L, Liu C, Long J, Ni Q, Yu X*. New insights into perineural invasion of pancreatic cancer: More than pain. Biochim Biophys Acta, 2016 Apr; 1865(2):111-22.
  9. Xiang J#, Liu L#, Wang W#, Xu H, Wu C, Xu J, Liu C, Long J, Ni Q, Yu X*. Metabolic tumor burden: a new promising way to reach precise personalized therapy in PDAC. Cancer Lett, 2015 Apr 10; 359(2):165-8.
  10. Liu L#, Xiang J#, Chen R, Fu D, Hong D, Hao J, Li Y, Li J, Li S, Mou Y, Mai G, Ni Q, Peng L, Qin R, Qian H, Shao C, Sun B, Sun Y, Tao M, Tian B, Wang H, Wang J, Wang L, Wang W, Wang W, Zhang J, Zhao G, Zhou J, Yu X*. Chinese Study Group for Pancreatic Cancer (CSPAC). The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates by the Chinese Study Group for Pancreatic Cancer (CSPAC). Int J Oncol, 2016 Mar; 48(3):900-7.
  11. Liu L#, Xu HX#, Wang WQ#, Wu CT, Xiang JF, Liu C, Long J, Xu J, Fu de L, Ni QX, Houchen CW, Postier RG, Li M, Yu XJ*. Serum CA125 is a novel predictive marker for pancreatic cancer metastasis and correlates with the metastasis-associated burden. Oncotarget, 2016 Feb 2; 7(5):5943-56.
  12. Luo G#, Guo M#, Jin K#, Liu Z, Liu C, Cheng H, Lu Y, Long J, Liu L, Xu J, Ni Q, Yu X*. Optimize CA19-9 in detecting pancreatic cancer by Lewis and Secretor genotyping. Pancreatology, 2016 Nov - Dec; 16(6):1057-1062.
  13. Wang WQ#, Liu L#, Xu HX#, Wu CT, Xiang JF, Xu J, Liu C, Long J, Ni QX, Yu XJ*. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma. Br J Surg, 2016 Aug; 103(9):1189-99.
  14. Liu Z#, Jin K#, Guo M, Long J, Liu L, Liu C, Xu J, Ni Q, Luo G, Yu X*. Prognostic Value of the CRP/Alb Ratio, a Novel Inflammation-Based Score in Pancreatic Cancer. Ann Surg Oncol, 2017 Feb; 24(2):561-568.
  15. Luo G#, Javed A#, Strosberg JR#, Jin K, Zhang Y, Liu C, Xu J, Soares K, Weiss MJ, Zheng L, Wolfgang CL, Cives M, Wong J, Wang W, Sun J, Shao C, Wang W, Tan H, Li J, Ni Q, Shen L, Chen M, He J, Chen J*, Yu X*. Modified Staging Classification for Pancreatic Neuroendocrine Tumors on the Basis of the American Joint Committee on Cancer and European Neuroendocrine Tumor Society Systems. J Clin Oncol, 2017 Jan 20; 35(3):274-280.
  16. Zhiwen Xiao#, Guopei Luo#, Zuqiang Liu, Kaizhou Jin, Jin Xu, Chen Liu, Liang Liu, Quanxing Ni,Jiang Long, Xianjun Yu*. Roux-en-Y pancreaticojejunostomy reconstruction after deep enucleation of benign or borderline pancreatic lesions: a single-institution experience. HPB (Oxford), 2016 Feb; 18(2):145-52.
  17. Guo M#, Luo G#, Liu C#, Cheng H, Lu Y, Jin K, Liu Z, Long J, Liu L, Xu J, Huang D, Ni Q, Yu X*. The Prognostic and Predictive Role of Epidermal Growth Factor Receptor in Surgical Resected Pancreatic Cancer. Int J Mol Sci, 2016 Jul 8; 17(7).
  18. Cheng H#, Liu C#, Cai X#, Lu Y, Xu Y, Yu X*. iPSCs Derived from Malignant Tumor Cells: Potential Application for Cancer Research. Curr Stem Cell Res Ther, 2016; 11(5):444-50.
  19. Liu C#, Lu Y#, Luo G#, Cheng H, Guo M, Liu Z, Xu J, Long J, Liu L, Fu D, Ni Q, Li M, Yu X*. Which patients with para-aortic lymph node (LN16) metastasis will truly benefit from curative pancreaticoduodenectomy for pancreatic head cancer? Oncotarget, 2016 May 17; 7(20):29177-86.
  20. Cheng H#, Luo G#, Lu Y, Jin K, Guo M, Xu J, Long J, Liu L, Yu X*, Liu C*. The combination of systemic inflammation-based marker NLR and circulating regulatory T cells predicts the prognosis of resectable pancreatic cancer patients. Pancreatology, 2016 Nov - Dec; 16(6):1080-1084.
  21. Xu HX#, Liu L#, Xiang JF, Wang WQ, Qi ZH, Wu CT, Liu C, Long J, Xu J, Ni QX, Yu XJ*. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma. Surgery, 2016 Nov 9. pii: S0039-6060(16)30422-6.
  22. Guopei Luo#, Chen Liu#, Meng Guo#, He Cheng, Yu Lu, Kaizhou Jin, Liang Liu, Jiang Long, Jin Xu, Renquan Lu, Quanxing Ni, Xianjun Yu*. Potential Biomarkers in Lewis Negative Patients with Pancreatic Cancer. Ann Surg, 2017 Apr; 265(4):800-805.
  23. Luo G#, Liu C#, Guo M#, Long J, Liu Z, Xiao Z, Jin K, Cheng H, Lu Y, Ni Q, Yu X*. CA19-9-Low&Lewis (+) pancreatic cancer: A unique subtype. Cancer Lett, 2016 Nov 10; 385:46-50.
  24. Chen Liu#, Rufu Chen, Yingtai Chen, Deliang Fu, Defei Hong, Jihui Hao, Dawei Liu, Jiangtao Li, Shengping Li, Yixiong Li, Gang Mai, Yiping Mou, Quanxing Ni, Li Peng, Honggang Qian, Renyi Qin, Bei Sun, Chenghao Shao, Yongwei Sun, Bole Tian, Jian Wang, Wei Wang, Weilin Wang, Gang Zhao, Xianjun Yu*. Should a standard lymphadenectomy during pancreatoduodenectomy exclude para-aortic lymph nodes for all cases of resectable pancreatic head cancer? A consensus statement by the Chinese Study Group for Pancreatic Cancer (CSPAC). Int J Oncol, 2015 Oct; 47(4):1512-6.
  25. Liu Z#, Luo G#, Guo M, Jin K, Xiao Z, Liu L, Liu C, Xu J, Ni Q, Long J, Yu X*. Lymph node status predicts the benefit of adjuvant chemoradiotherapy for patients with resected pancreatic cancer. Pancreatology, 2015 May-Jun; 15(3):253-8.
  26. Jin K#, Luo G#, Xiao Z, Liu Z, Liu C, Ji S, Xu J, Liu L, Long J, Ni Q, Yu X*. Noncoding RNAs as potential biomarkers to predict the outcome in pancreatic cancer. Drug Des Devel Ther, 2015 Feb 26; 9:1247-55.
  27. Guopei Luo#, Zuqiang Liu#, Meng Guo, Kaizhou Jin, Zhiwen Xiao, Liang Liu, Chen Liu, Jin Xu, Quanxing Ni, Jiang Long, Xianjun Yu*. A comprehensive comparison of clinicopathologic and imaging features of incidental/symptomatic non-functioning pancreatic neuroendocrine tumors: A retrospective study of a single center. Pancreatology, 2015; 15(5):519-524.
  28. Xiang J#, Liu L#, Wang W, Xu H, Wu C, Xu J, Liu C, Long J, Ni Q, Yu X*. Metabolic tumor burden: a new promising way to reach precise personalized therapy in PDAC. Cancer Lett, 2015 Apr 10; 359(2):165-8.
  29. Guopei Luo#, Yu Lu#, Kaizhou Jin, He Cheng, Meng Guo, Zuqiang Liu, Jiang Long, Chen Liu, Quanxing Ni, Xianjun Yu*. Pancreatic cancer: BRCA mutation and personalized treatment. Expert Review of Anti-infective Therapy, 2015; 15(10):1223-1231.
  30. Xu Y#, Lu Y#, Cheng H#, Jiang J, Xu J, Long J, Liu L, Ni Q, Liu C, Yu X*. High Expression of Human Leukocyte Antigen-G is Associated with a Poor Prognosis in Patients with PDAC. Current Molecular Medicine, 2015; 15(4):360-7.
  31. Luo G#, Guo M#, Liu Z, Xiao Z, Jin K, Long J, Liu L, Liu C, Xu J, Ni Q, Yu X*. Blood neutrophil-lymphocyte ratio predicts survival in patients with advanced pancreatic cancer treated with chemotherapy. Ann Surg Oncol, 2015 Feb; 22(2):670-6.
  32. Xu J#, Zhang B#, Shi S#, Qin Y, Ji S, Xu W, Liu J, Liu L, Liu C, Long J, Ni Q, Yu X*. Papillary-like main pancreatic duct invaginated pancreaticojejunostomy versus duct-to-mucosa pancreaticojejunostomy after pancreaticoduodenectomy: A prospective randomized trial. Surgery, 2015 Nov; 158(5):1211-8.
  33. Tao Chen#, Min-Gui Zhang, Hua-Xiang Xu, Wen-Quan Wang, Liang Liu, Xian-Jun Yu*. Preoperative Serum CA125 Levels Predict the Prognosis in Hyperbilirubinemia Patients With Resectable Pancreatic Ductal Adenocarcinoma. Medicine, 2015; 94:1-10.
  34. Shunrong Ji#, Yi Qin#, Si Shi#, Xiangyuan Liu, Hongli Hu, Hu Zhou, Jing Gao, Bo Zhang, Wenyan Xu, Jiang Liu, Dingkong Liang, Liang Liu, Chen Liu, Jiang Long, Haijun Zhou, Paul J.Chiao, Jin Xu, Quanxing Ni, Daming Gao, Xianjun Yu*. ERK kinase phosphorylates and destabilizes the tumor suppressor FBW7 in pancreatic cancer. Cell Res, 2015 May; 25(5):561-73.
  35. Si Shi#, Shunrong Ji#, Yi Qin#, Jin Xu, Bo Zhang, Wenyan Xu, Jiang Liu, Jiang Long, Chen Liu, Liang Liu, Quanxing Ni, Xianjun Yu*. Metabolic tumor burden is associated with major oncogenomic alterations and serum tumor markers in patients with resected pancreatic cancer. Cancer Lett, 2015 May 1; 360(2):227-33.
  36. Liu L#, Xu H#, Wang W#, Wu C#, Chen Y, Yang J, Cen P, Xu J, Liu C, Long J, Guha S, Fu D, Ni Q, Jatoi A, Chari S, McCleary-Wheeler AL, Fernandez-Zapico ME, Li M, Yu X*. A preoperative serum signature of CEA+ /CA125+ /CA19-9 ≥ 1000 U/mL indicates poor outcome to pancreatectomy for pancreatic cancer. Int J Cancer, 2014; 136(9):2216–2227.
  37. Wantong Yao#, Shunrong Ji#, Yi Qin#, Jingxuan Yang, Jin Xu, Bo Zhang, Wenyan Xu, Jiang Liu, Si Shi, Liang Liu, Chen Liu, Jiang Long, Quanxing Ni, Min Li, Xianjun Yu*. Profilin-1 suppresses tumorigenicity in pancreatic cancer through regulation of the SIRT3-HIF1α axis. Molecular Cancer, 2014 Aug 7; 13:187.
  38. GUOPEI LUO#, ZUQIANG LIU#, MENG GUO#, KAIZHOU JIN, ZHIWEN XIAO, LIANG LIU, JIN XU, BO ZHANG, CHEN LIU, DAN HUANG, SILONG HU, QUANXING NI, JIANG LONG, XIANJUN YU*.18F-FDG PET/CT can be used to detect non-functioning pancreatic neuroendocrine tumors. INTERNATIONAL JOURNAL OF ONCOLOGY, 2014 Oct; 45(4):1531-6.
  39. Yong-Feng Xu#, Yu Lu#, He Cheng#, Si Shi, Jin Xu, Jiang Long, Liang Liu, Chen Liu, Xianjun Yu*. Abnormal distribution of peripheral lymphocyte subsets induced by PDAC modulates overall survival. Pancreatology, 2014 Jul-Aug; 14(4):295-301. 
  40. Wang WQ#, Liu L#, Xu HX#, Sun HC, Wu CT, Zhu XD, Zhang W, Xu J, Liu C, Long J, Ni QX, Tang ZY, Yu XJ*. The combination of HTATIP2 expression and microvessel density predicts converse survival of hepatocellular carcinoma with or without sorafenib. Oncotarget, 2014 Jun 15; 5(11):3895-906.
  41. Long J#, Luo GP, Xiao ZW, Liu ZQ, Guo M, Liu L, Liu C, Xu J, Gao YT, Zheng Y, Wu CT, Ni QX, Li M, Yu XJ*. Cancer statistics: Current diagnosis and treatment of pancreatic cancer in Shanghai, China. Cancer Lett, 2014 May 1; 346(2):273-7.
  42. Qin Y#, Zhu WW#, Xu WY#, Zhang B, Shi S, Ji SR, Liu J, Long J, Liu C, Liu L, Xu J, Yu XJ*. LSD1 sustains pancreatic cancer growth via maintaining HIF1α-dependent glycolytic process. Cancer Lett, 2014 Jun 1; 347(2):225-32.
  43. Xu HX#, Chen T#, Wang WQ#, Wu CT#, Liu C, Long J, Xu J, Zhang YJ, Chen RH, Liu L, Yu XJ*. Metabolic tumour burden assessed by 18F-FDG PET/CT associated with serum CA19-9 predicts pancreatic cancer outcome after resection. Eur J Nucl Med Mol Imaging, 2014 Jun; 41(6):1093-102.
  44. Lu Y#, Liu C#, Xu YF#, Cheng H, Shi S, Wu CT, Yu XJ*. Stathmin destabilizing microtubule dynamics promotes malignant potential in cancer cells by epithelial-mesenchymal transition. Hepatobiliary Pancreat Dis Int, 2014; 13(4): 386-395.
  45. Lu Y#, Liu C#, Cheng H, Xu YF, Jiang JH, Xu J, Long J, Liu L, Yu XJ*. Stathmin, interacting with Nf-κB, promotes tumor growth and predicts poor prognosis of pancreatic cancer. Curr Mol Med, 2014 Mar; 14(3):328-39.
  46. Shi S#, Lu Y#, Qin Y, Li W, Cheng H, Xu YF, Xu J, Long J, Liu L, Liu C, Yu XJ*. miR-1247 is correlated with prognosis of pancreatic cancer and inhibits cell proliferation by targeting neuropilins. Curr Mol Med, 2014 Mar; 14(3):316-27.
  47. Jia-Hao Jiang#, Chen Liu#, He Cheng, Yu Lu, Yi Qin, Yong-Feng Xu, Jin Xu, Jiang Long, Liang Liu, Quan-Xing Ni, Xian-Jun Yu*. Epithelial–mesenchymal transition in pancreatic cancer: Is it a clinically significant factor? Biochimica et Biophysica Acta, 2015 Jan; 1855(1):43-9.
  48. Xiao ZW#, Luo GP#, Liu C, Wu CT, Liu L, Liu ZQ, Ni QX, Long J, Yu XJ*. Molecular Mechanism Underlying Lymphatic Metastasis in Pancreatic Cancer. BioMed Research International, 2014; 2014:925845.
  49. Wu CT#, Xu WY#, Liu L, Long J, Xu J, Ni QX, Liu C, Yu XJ*. Ligamentum teres hepatis patch enhances the healing of pancreatic fistula after distal pancreatectomy. Hepatobiliary Pancreat Dis In, 2013 Dec; 12(6):651-5.
  50. Liu L#, Xu HX#, Wang WQ#, Wu CT#, Chen T, Qin Y, Liu C, Xu J, Long J, Zhang B, Xu YF, Ni QX, Li M, Yu XJ*. Cavin-1 is essential for the tumor-promoting effect of caveolin-1 and enhances its prognostic potency in pancreatic cancer. Oncogene, 2014 May 22; 33(21):2728-36.
  51. Luo GP#, Xiao ZW#, Long J#, Liu ZQ, Liu L, Liu C, Xu J, Ni QX, Yu XJ*. CA125 is Superior to CA19-9 in Predicting the Resectability of Pancreatic Cancer. J Gastrointest Surg, 2013; 17(12): 2092-2098.
  52. Xu J#, Zhu WW#, Xu WY#, Yao WT, Zhang B, Xu YF, Ji SR, Liu C, Long J, Ni QX, Yu XJ*. Up-regulation of MBD1 Promotes Pancreatic Cancer Cell Epithelial-Mesenchymal Transition and Invasion by Epigenetic Down-regulation of E-cadherin. Curr Mol Med, 2013; 13(3): 387-400.
  53. Liu C#, Long J#, Liu L, Xu J, Zhang B, Yu XJ*, Ni QX. Pancreatic stump-closed pancreaticojejunostomy can be performed safely in normal soft pancreas cases. J Surg Res, 2012 Jan; 172(1):e11-7
  54. Wu CT#, Xu WY#, Liu L#, Long J, Xu J, Ni QX, Liu C, Yu XJ*. Ligamentum teres hepatis patch enhances the healing of pancreatic fistula after distal pancreatectomy. Hepatobiliary Pancreat Dis Int, 2013 Dec; 12(6):651-5.
  55. Wang WQ#, Liu L#, Xu HX#, Luo GP, Chen T, Wu CT, Xu YF, Xu J, Liu C, Zhang B, Long J, Tang ZY, Yu XJ*. Intratumoral α-SMA Enhances the Prognostic Potency of CD34 Associated with Maintenance of Microvessel Integrity in Hepatocellular Carcinoma and Pancreatic Cancer. PLoS One, 2013; 5(8):71189.
  56. Zhang B#, Xu J#, Liu C, Long J, Liu L, Xu YF, Wu CT, Luo GP, Ni QX, Li M, Yu XJ*. Application of "papillary-like main pancreatic duct invaginated" pancreaticojejunostomy for normal soft pancreas cases. Sci Rep, 2013; 3(1): 2068-2073.
  57. Cheng H#, Li J#, Liu C#, Yao W, Xu Y, Frank TS, Cai X, Shi S, Lu Y, Qin Y, Liu L, Xu J, Long J, Ni QX, Li M, Yu XJ*. Profilin1 Sensitizes Pancreatic Cancer Cells to irradiation by Inducing Apoptosis and Reducing Autophagy. Curr Mol Med, 2013; 13(8):1368-1375.
  58. Chen T#, Liu L, Xu HX, Wang WQ, Wu CT, Yao WT, Yu XJ*. Significance of caveolin-1 regulators in pancreatic cancer. Asian Pac J Cancer Prev, 2013; 14(8):4501-4507.
  59. Liu C#, Cheng H#, Shi S#, Cui X, Yang J, Chen L, Cai XC, Lu Y, Wu CT, Yao WT, Qin Y, Liu L, Long J, Xu J, Li M, Yu XJ*. MicroRNA-34b inhibits pancreatic cancer metastasis through repressing Smad3. Curr Mol Med, 2013; 13(4): 467-478.
  60. Xu J#, Zhu WW#,  Xu WY#, Cui X, Chen L, Ji SR, Qin Y, Yao WT, Liu L, Liu C, Long J, Li M, Yu XJ*. Silencing MBD1 Reverses Pancreatic Cancer Therapy Resistance through Inhibiting DNA Damage Repair. Int J Oncol, 2013; 42(6): 2046-2052.
  61. Yao WT#, Cai XC#, Liu C#, Qin Y, Cheng H, Ji SR, Xu WY, Wu CT, Chen T, Xu J, Long J, Fang Z, Qu B, Hoth M, Ni QX, Zha XL, Yu XJ*. Profilin1 potentiates apoptosis induced by staurosporine in cancer cells. Curr Mol Med, 2013; 13(3): 417-428.
  62. Luo GP#, Long J#, Cui X, Xiao ZW, Liu ZQ, Shi S, Liu L, Liu C, Xu J, Li M, Yu XJ*. Highly lymphatic metastatic pancreatic cancer cells possess stem cell-like properties. Int J Oncol, 2013; 42(3):979-984.
  63. Long J#, Luo GP#, Liu C, Cui X, Satoh K, Xiao ZW, Zhang B, Xu J, Ni QX, Li M, Yu XJ*. Development of a unique mouse model for pancreatic cancer lymphatic metastasis. Int J Oncol, 2012; 41(5):1662-1668.
  64. Cheng H#, Shi S, Cai XC, Long J, Xu J, Liu C, Yu XJ*. microRNA signature for human pancreatic cancer invasion and metastasis. Exp Ther Med, 2012; 4(2):181-187.
  65. Luo GP#, Long J, Zhang B, Liu C, Xu J, Ni QX, Yu XJ*. Stroma and pancreatic ductal adenocarcinoma: An interaction loop. BBA-REV CANCER, 2012; 1826(1): 170-178.
  66. Ji SR#, Xu J#, Zhang B, Xu YF, Liu C, Long J, Ni QX, Yu XJ*. Management of a malignant case of solid pseudopapillary tumor of pancreas: a case report and literature review. Pancreas, 2012; 41(8):1336-1340.
  67. Yao WT#Yu XJ#, Fang Z, Yin P, Zhao C, Li N, Wang L, Li Z, Zha XL*. Profilin1 facilitates staurosporine-triggered apoptosis by stabilizing the integrin β1–actin complex in breast cancer cells. J Cell Mol Med, 2012; 4(16):824-835.
  68. Ji SR#, Xu J#, Zhang B, Yao WT, Xu WY, Wu W, Xu YF, Wang H, Ni QX, Hou H, Yu XJ*. RGD-conjugated albumin nanoparticles as a novel delivery vehicle in pancreatic cancer therapy. Cancer Biol Ther, 2012; 13(4):206-215.
  69. Shi S#, Yao WT#, Xu J, Long J, Liu C, Yu XJ*. Combinational therapy: New hope for pancreatic cancer? Cancer Lett, 2012; 317(2):127-135.
  70. Luo GP#, Long J#, Zhang B, Liu C, Ji SR, Xu J, Yu XJ*, Ni Q. Quantum dots in cancer therapy. Expert Opin Drug Deliv, 2012; 9(1):47-58.
  71. Luo GP#, Long J#, Qiu L, Liu C, Xu J, Yu XJ*. Role of epidermal growth factor receptor expression on patient survival in pancreatic cancer: a meta-analysis. Pancreatology, 2011; 11(6):595-600.
  72. Ji SR#, Liu C, Zhang B, Yang F, Xu J, Long J, Jin C, Fu DL, Ni QX, Yu XJ*. Carbon nanotubes in cancer diagnosis and therapy. BBA-REV CANCER, 2010; 1806(1):29-35.
  73. Luo GP#, Long J, Zhang B, Liu C, Xu J, Yu XJ*, Ni Q. Developmental plasticity of stem cells and diseases. Med Hypotheses, 2010; 75(6):507-510.
  74. Yu XJ#, Zhang Y, Chen C, Yao Q, Li M*.Targeted drug delivery in pancreatic cancer. BBA-REV CANCER, 2010; 1805(1):97-104.
  75. Luo GP#Yu XJ*, Jin C, Yang F, Fu DL, Long J, Xu J, Zhan C, Lu W. LyP-1-conjugated nanoparticles for targeting drug delivery to lymphatic metastatic tumors. Int J Pharm, 2010; 385(1-2): 150-156.
 
复旦大学肿瘤研究所 通讯地址: 东安路270号2号楼1312室 64175590-5312 Email:fuci2012@126.com
Copyright 2013 shca.org.cn All rights reserved. 复旦大学肿瘤研究所 版权所有